Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02775851 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
A Phase 2 study of Desmoplastic Melanoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
- 20
- Study locations
NCT02775851 is a Phase 2 study of Desmoplastic Melanoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 57 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT02775851, a Phase 2 study of Desmoplastic Melanoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
- 20
- Study locations
Study Summary
This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can be removed by surgery (resectable) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- PROCEDURE Magnetic Resonance Elastography
Study Locations (20)
California
- Mission Hope Medical Oncology - Arroyo Grande - Arroyo Grande
- City of Hope Comprehensive Cancer Center - Duarte
- Epic Care-Dublin - Dublin
- Bay Area Breast Surgeons Inc - Emeryville
- Epic Care Partners in Cancer Care - Emeryville
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Contra Costa Regional Medical Center - Martinez
- USC Norris Oncology/Hematology-Newport Beach - Newport Beach
- Alta Bates Summit Medical Center - Summit Campus - Oakland
- Bay Area Tumor Institute - Oakland
- Keck Medical Center of USC Pasadena - Pasadena
- Pacific Central Coast Health Center-San Luis Obispo - San Luis Obispo
- Mission Hope Medical Oncology - Santa Maria - Santa Maria
- City of Hope South Pasadena - South Pasadena
Arkansas
- Mercy Hospital Fort Smith - Fort Smith
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
Alaska
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- Cancer Center at Saint Joseph's - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2017-02-06 |
| Est. Completion | 2026-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02775851
The ClinicalTrials.gov registry entry for NCT02775851 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Desmoplastic Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02775851 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alaska.
Frequently Asked Questions
What is clinical trial NCT02775851 about?
NCT02775851 is a clinical study titled "Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery". This pilot phase II trial studies how well pembrolizumab works in treating patients with desmoplastic melanoma (DM) that can be removed by surgery (resectable) or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune ...
What is the current status of trial NCT02775851?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2017-02-06. Estimated completion is 2026-05-15.
What conditions does trial NCT02775851 study?
This clinical trial studies the following conditions: Desmoplastic Melanoma.
What interventions are being tested in trial NCT02775851?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Magnetic Resonance Elastography (PROCEDURE).
Who is sponsoring clinical trial NCT02775851?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02775851 being conducted?
This trial has 20 study locations across Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.